<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795184</url>
  </required_header>
  <id_info>
    <org_study_id>MKT-2008-BE-01</org_study_id>
    <nct_id>NCT00795184</nct_id>
  </id_info>
  <brief_title>Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy</brief_title>
  <acronym>DONTBIOPCE</acronym>
  <official_title>Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mauna Kea Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cellvizio Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emissary International LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mauna Kea Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will collect data from patients routinely undergoing a endoscopic surveillance and
      Cellvizio endomicroscopy procedure due to confirmed Barrett's esophagus. The objective is to
      determine if endomicroscopy images collected using the marketed Cellvizio device may help
      endoscopists more accurately diagnose, in conjunction with traditional tissue sampling
      techniques, whether a suspected lesion is malignant or benign.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a longitudinal observational study were imaging procedures are allocated in a random
      order to directly address the low sensitivity and specificity of enhanced macroscopic
      endoscopic imaging devices by determining whether probe-based Confocal Laser Endomicroscopy
      (pCLE), as a supplement to Narrow Band Imaging (NBI) can further improve sensitivity and
      specificity to a level that would be acceptable to avoid random biopsy, and better direct
      biopsy of suspicious areas. The study is also addressing pCLE as a supplement to standard
      white light endoscopy and random biopsy alone. In fact, the study is powered to evaluate per
      lesion sensitivity and specificity of confocal imaging as applied to lesions identified by
      white light endoscopy. Therefore, the study addresses the shortcomings of standard white
      light endoscopy (high number of random biopsies, less than ideal directed biopsy of
      suspicious areas) and the primary shortcomings of Narrow Band Imaging (NBI) (low specificity
      with resultant high false positives, again resulting in many unnecessary biopsies).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparative Histopathology-confirmed Measures of Per Lesion Sensitivity and Per Lesion Specificity, by Using pCLE Associated With WLE, or WLE Alone, for the Detection of High Grade Dysplasia and Early Carcinoma in Barrett's Esophagus.</measure>
    <time_frame>Centralized histopathology confirmation within 4-6 weeks</time_frame>
    <description>Comparative Histopathology-confirmed Measures of Per Lesion Sensitivity and Per Lesion Specificity, by Using Probe-based Confocal Laser Endomicroscopy (pCLE) Associated With White Light Endoscopy (WLE), or WLE Alone, for the Detection of High Grade Dysplasia and Early Carcinoma in Barrett's Esophagus.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Barrett Syndrome</condition>
  <condition>Barrett's Syndrome</condition>
  <condition>Barrett's Esophagus</condition>
  <condition>Barrett Esophagus</condition>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Imaging Procedures HDWLE first NBI second and pCLE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients undergo both endoscopic imaging procedures and then the endomicroscopy procedure; the endoscopic imaging procedures being performed back to back by two endoscopists, blinded to each other.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imaging Procedures NBI first HDWLE second and pCLE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients undergo both endoscopic imaging procedures and then the endomicroscopy procedure; the endoscopic imaging procedures being performed back to back by two endoscopists, blinded to each other.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Imaging procedures (NBI)</intervention_name>
    <description>Imaging procedures (pCLE) and (NBI) - All patients undergo both procedures back to back by two endoscopists, blinded to each other, in randomized order.
Procedure 1: Standard endoscopic procedure The patient receives white light endoscopy (WLE) examination. All visible lesions are noted and photographed. No biopsy is taken until both procedures are complete.
Procedure 2: NBI endoscopic procedure The patient receives a NBI endoscopy examination. All visible and NBI abnormal lesions are noted and photographed.
After both procedures are complete and all sites are unblinded to both endoscopists. pCLE with Cellvizio and physical biopsies are performed at all sites plus 4 quadrant sites.</description>
    <arm_group_label>Imaging Procedures HDWLE first NBI second and pCLE</arm_group_label>
    <arm_group_label>Imaging Procedures NBI first HDWLE second and pCLE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HDWLE</intervention_name>
    <arm_group_label>Imaging Procedures HDWLE first NBI second and pCLE</arm_group_label>
    <arm_group_label>Imaging Procedures NBI first HDWLE second and pCLE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>pCLE</intervention_name>
    <arm_group_label>Imaging Procedures HDWLE first NBI second and pCLE</arm_group_label>
    <arm_group_label>Imaging Procedures NBI first HDWLE second and pCLE</arm_group_label>
    <other_name>Cellvizio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with documented or suspected Barrett's esophagus presenting for endoscopy

          2. Age &gt; 18 years

          3. Ability to provide written, informed consent

        Exclusion Criteria:

          1. Presence of erosive esophagitis

          2. Inability to obtain biopsies due to anticoagulation, varices, etc.

          3. Allergy to fluorescein, pregnancy

          4. Presence of an esophageal mass other than small 10mm or less nodules

          5. Renal insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prateek Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veterans Affairs Hospital, Kansas City</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital/Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Nantes</city>
        <zip>44093 Cedex 1</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sharma P, Meining AR, Coron E, Lightdale CJ, Wolfsen HC, Bansal A, Bajbouj M, Galmiche JP, Abrams JA, Rastogi A, Gupta N, Michalek JE, Lauwers GY, Wallace MB. Real-time increased detection of neoplastic tissue in Barrett's esophagus with probe-based confocal laser endomicroscopy: final results of an international multicenter, prospective, randomized, controlled trial. Gastrointest Endosc. 2011 Sep;74(3):465-72. doi: 10.1016/j.gie.2011.04.004. Epub 2011 Jul 13.</citation>
    <PMID>21741642</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <results_first_submitted>June 4, 2012</results_first_submitted>
  <results_first_submitted_qc>May 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 3, 2016</results_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Barrett's Esophagus</keyword>
  <keyword>EsoGastroDuodenoscopy</keyword>
  <keyword>Barrett's Carcinoma</keyword>
  <keyword>adenocarcinoma</keyword>
  <keyword>Cellvizio</keyword>
  <keyword>endomicroscopy</keyword>
  <keyword>random biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HDWLE First NBI Second and pCLE</title>
        </group>
        <group group_id="P2">
          <title>NBI First HDWLE Second and pCLE</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57">57 patients analysable, completed all 3 imaging procedures</participants>
                <participants group_id="P2" count="44">44 patients analysable, completed all 3 imaging procedures</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Tissue sampling incomplete/conclusive</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>NBI-pCLE</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.1" spread="11.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparative Histopathology-confirmed Measures of Per Lesion Sensitivity and Per Lesion Specificity, by Using pCLE Associated With WLE, or WLE Alone, for the Detection of High Grade Dysplasia and Early Carcinoma in Barrett’s Esophagus.</title>
        <description>Comparative Histopathology-confirmed Measures of Per Lesion Sensitivity and Per Lesion Specificity, by Using Probe-based Confocal Laser Endomicroscopy (pCLE) Associated With White Light Endoscopy (WLE), or WLE Alone, for the Detection of High Grade Dysplasia and Early Carcinoma in Barrett’s Esophagus.</description>
        <time_frame>Centralized histopathology confirmation within 4-6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HDWLE</title>
          </group>
          <group group_id="O2">
            <title>NBI (Narrow Band Imaging)</title>
          </group>
          <group group_id="O3">
            <title>pCLE</title>
          </group>
          <group group_id="O4">
            <title>HDWLE+NBI+pCLE</title>
          </group>
          <group group_id="O5">
            <title>HDWLE+pCLE</title>
          </group>
          <group group_id="O6">
            <title>HDWLE+NBI</title>
          </group>
        </group_list>
        <measure>
          <title>Comparative Histopathology-confirmed Measures of Per Lesion Sensitivity and Per Lesion Specificity, by Using pCLE Associated With WLE, or WLE Alone, for the Detection of High Grade Dysplasia and Early Carcinoma in Barrett’s Esophagus.</title>
          <description>Comparative Histopathology-confirmed Measures of Per Lesion Sensitivity and Per Lesion Specificity, by Using Probe-based Confocal Laser Endomicroscopy (pCLE) Associated With White Light Endoscopy (WLE), or WLE Alone, for the Detection of High Grade Dysplasia and Early Carcinoma in Barrett’s Esophagus.</description>
          <units>percentage of lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="101"/>
                <count group_id="O6" value="101"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Biopsy sites</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="874"/>
                <count group_id="O2" value="874"/>
                <count group_id="O3" value="874"/>
                <count group_id="O4" value="874"/>
                <count group_id="O5" value="874"/>
                <count group_id="O6" value="874"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2" lower_limit="25.7" upper_limit="42.7"/>
                    <measurement group_id="O2" value="41.7" lower_limit="32.8" upper_limit="50.5"/>
                    <measurement group_id="O3" value="62.5" lower_limit="53.8" upper_limit="71.2"/>
                    <measurement group_id="O4" value="75.8" lower_limit="68.2" upper_limit="83.5"/>
                    <measurement group_id="O5" value="68.3" lower_limit="60.0" upper_limit="76.7"/>
                    <measurement group_id="O6" value="45.0" lower_limit="36.1" upper_limit="53.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7" lower_limit="90.8" upper_limit="94.6"/>
                    <measurement group_id="O2" value="90.5" lower_limit="88.4" upper_limit="92.5"/>
                    <measurement group_id="O3" value="92.7" lower_limit="90.8" upper_limit="94.6"/>
                    <measurement group_id="O4" value="84.2" lower_limit="81.6" upper_limit="86.8"/>
                    <measurement group_id="O5" value="87.8" lower_limit="85.5" upper_limit="90.1"/>
                    <measurement group_id="O6" value="88.2" lower_limit="85.9" upper_limit="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Acutely during the procedure - within the day</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>NBI-pCLE or pCLE-NBI</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christophe Bailleul</name_or_title>
      <organization>Mauna Kea Technologies</organization>
      <phone>+ 33 1 70 08 09 74</phone>
      <email>christopheb@maunakeatech.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

